I also emailed the company last week regarding the lymphocyte counts, yet to receive a response. With everything going on I didn't expect a reply anytime soon; however it could have been addressed in yesterday's letter. As it wasn't I now assume from a discloser perspective all three outcome measures of the trial were communicated in the topline announcement:
Primary: PUL 2.0 did not meet its primary endpoint
Secondary: 'no statistically significant differences in efficacy'
Other Outcome Measures - lymphocyte: 'nor was there a clear directional trend toward benefit'. (wording is consistent with previous announcements/papers)
For a number of years, the key message has been Avicursen as an anti-inflammatory therapy. To immediately terminate the trial as part of the announcement you would think topline data for all three trial measures, especially lymphocyte relating inflammation, was available and disclosed to the market; even if it is somewhat vague.
I see today as a likely positive. Not sure what's going to eventuate over the coming weeks. Moses was the chair for 20 years until 2021 before endorsing the appointment of Charmaine. Who knows what his reasons are; but at the very least he's given us an opportunity to have a say that didn't exist beforehand.
PER Price at posting:
0.9¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)